Alpelisib

Drug Profile

Alpelisib

Alternative Names: BYL-719; NVP-BYL-719

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; Northwestern University; Novartis; Novartis Oncology; Peter MacCallum Cancer Centre; University Health Network
  • Class Amides; Antineoplastics; Dicarboxylic acids; Fluorine compounds; Pyridines; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Head and neck cancer; Multiple myeloma; Oesophageal cancer
  • Phase I Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer; Rectal cancer; Uveal melanoma
  • Discontinued Solid tumours

Most Recent Events

  • 08 Jul 2017 Novartis completes a phase II trial in Breast cancer (Combination therapy, Neoadjuvant therapy) in US, Austria, Australia, Belgium, Canada, Germany, Netherlands, Hong Kong, Italy and Spain (NCT01923168)
  • 06 Jul 2017 M.D. Anderson Cancer Center, in collaboration with Novartis and Astellas Pharma, plans a phase I trial for Breast Cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03207529)
  • 05 Jul 2017 Novartis initiates enrolment in a phase II trial for Breast Cancer (Combination therapy, Late-stage disease, Second line or greater) in USA (NCT03056755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top